东陽光药

# SUNSHINE LAKE PHARMA CO., LTD.

# 廣東東陽光藥業股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6887)**

## VOLUNTARY ANNOUNCEMENT (1) UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS; AND (2) BUSINESS UPDATE

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

### (1) UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

The board (the "**Board**") of directors (the "**Directors**") of the Company has noted the unusual movements in the price and trading volume of the shares of the Company today. Having made reasonable enquiries, the Board confirms that, as of the date of this announcement, it is not aware of any reasons for these price and trading volume movements or any information that needs to be disclosed to avoid a false market in the Company's securities, or any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board confirms that the Group's business operations remain normal, and that there is no material change to the business operation and financial position of the Group as of the date of this announcement.

### (2) BUSINESS UPDATE

The insulin glargine injection independently developed by the Group has obtained marketing approval from the U.S. Food and Drug Administration. Shipment of this product is scheduled to be arranged in the near future. Subject to successful shipment of the product, the Group expects to commence official commercialization of the product in the U.S. market in due course. This milestone will further expand the Company's overseas revenue streams, boost the global competitiveness of the Company's anti-diabetic medications, and accelerate the implementation of our internationalization and industrialization strategic layout.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.**

By order of the Board
**Sunshine Lake Pharma Co., Ltd.**
**Dr. ZHANG Yingjun**
*Chairman*

Dongguan, the PRC
17 July 2026

*As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfa, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.*